RRMS

Changes in mitochondria — cells’ energy production centers — are evident in early disease stages in a mouse model of progressive multiple sclerosis (MS), but were not found in a model of relapsing-remitting MS (RRMS), according to researchers. These changes, seen before symptoms of the disease started, were…

Evobrutinib, an experimental BTK inhibitor being developed for people with relapsing forms of multiple sclerosis (MS), continues to be well tolerated and is showing low relapse rates after four years of treatment. That’s according to new data spanning a Phase 2 trial (NCT02975349) that tested evobrutinib against…

An eight-week intermittent fasting intervention for people with relapsing-remitting multiple sclerosis (RRMS) led to significant improvements in cognition and manual dexterity for these patients, who also tended to have lower fatigue and pain scores at the program’s end, an exploratory study showed.

Long-term use of Zeposia (ozanimod) did not adversely affect the heart of relapsing multiple sclerosis (MS) patients treated for one or two years in Phase 3 clinical trials, with no clinically significant changes in cardiac function reported. Data on people enrolled in the two studies were retrospectively evaluated, as the therapy…

Treatment with CNM-Au8, an experimental oral liquid therapy, led to statistically significant improvements in the health of connections between brain regions for people with stable relapsing-remitting multiple sclerosis (RRMS). That’s according to new MRI data from the Phase 2 VISIONARY-MS trial (NCT03536559), which tested CNM-Au8 against a placebo in…

Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis (RRMS), a small study from Turkey suggests. Over about 2.5 years of the treatment, these pediatric patients experienced no relapses or MRI activity, and their disability level also improved, indicating…

PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in people with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

TG Therapeutics’ Briumvi (ublituximab-xiiy), a CD20 inhibitor recently approved for adults with relapsing forms of multiple sclerosis (MS), is now commercially available in the U.S., the company announced. The treatment was approved in the U.S. late last year, with indications that include clinically isolated syndrome, relapsing-remitting MS (RRMS),…

Patient dosing has begun in a Phase 2 trial testing Denali Therapeutics‘ investigational oral RIPK1 inhibitor SAR443820 in people with multiple sclerosis (MS). The clinical trial (NCT05630547) seeks to enroll about 168 patients, age 18–60, with either relapsing-remitting MS (RRMS), active and nonactive secondary progressive…

Ocrevus (ocrelizumab) seems to be equally effective at stabilizing disease activity in Black and white patients with relapsing-remitting multiple sclerosis (RRMS), a U.S. study found. Disability levels and MRI disease markers remained generally unchanged over the two-year study in both groups, despite Black patients having more severe disability…

People with relapsing-remitting multiple sclerosis (RRMS) who are receiving oral disease-modifying therapies (DMTs) are still more likely to experience a relapse or any form of disease activity if they are smokers, a study found. Researchers also observed that former smokers had a disease…

Aerobic training for up to three months significantly outperformed less-strenuous exercise at improving walking capacity among people with multiple sclerosis (MS), a new study reports. However, the benefits of aerobic exercise seem to be greater among patients without MS-related damage in the insula — a brain region involved in…

Researchers in Iran are conducting a clinical trial to test the effects of taking ginger supplements for people with relapsing-remitting multiple sclerosis (RRMS). Ginger extracts have shown some promise in animal models of multiple sclerosis (MS), but no trial has yet determined the impact that ginger supplements may…

The U.S. Food and Drug Administration has approved TG Therapeutics‘ B-cell-depleting therapy ublituximab under the brand name Briumvi for the treatment of adults with relapsing forms of multiple sclerosis (MS), the company announced. The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive…

Ocrevus (ocrelizumab) was equally effective in reducing disease activity after two years in people with primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS), a new study reports. The therapy also slowed disease progression in both groups, although a stronger effect was seen with RRMS patients…

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

Researchers have created a computer program that can simulate clinical trial responses for relapsing-remitting multiple sclerosis (RRMS), which may improve clinical trial design for novel disease-modifying therapies. The tool, called MS TreatSim, was described in the study, “In silico clinical trials for relapsing-remitting multiple sclerosis…

More than four years of treatment with Gilenya (fingolimod) did not cause significant swelling of the macula — a part of the retina, found in the back of the eye, and important for visual clarity — in people with relapsing-remitting multiple sclerosis (RRMS), a small study showed. While…

People with relapsing-remitting multiple sclerosis (RRMS) who are stable on rituximab treatment may receive the therapy at extended intervals without risking increased MS disease activity, according to a new study. In fact, a longer lag between infusions could potentially reduce the medication’s side effects, researchers say — noting,…

A reduction in the levels of an inflammatory molecule called chemokine ligand 13 (CXCL13) may serve as a biomarker of treatment response to Aubagio (teriflunomide) among people with relapsing-remitting multiple sclerosis (RRMS), a study suggests. After one year of treatment, patients with no evidence of disease activity…

Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume — two markers of neurodegeneration — in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…

People with relapsing-remitting multiple sclerosis (RRMS) who switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) or Tysabri (natalizumab), according to a new study. Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched…

A dietary supplement called Neuroaspis plp10 significantly lowered relapse rates and slowed disability progression among people with relapsing-remitting multiple sclerosis (RRMS) on interferon beta medications, according to a small clinical trial in Greece. “The results of this study suggest that Neuroaspis plp10 may offer greater benefit to patients with RRMS…

Most adults with relapsing-remitting multiple sclerosis (RRMS) who received Immunic Therapeutics‘ investigational therapy vidofludimus calcium have had no confirmed disability progression after two years of treatment. That’s according to new interim data from the open-label extension portion of the EMPhASIS trial, which has been running for nearly…

Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, and secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those for relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. “A bigger healthcare resource consumption was retrieved for…

Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues to maintain MS relapse rates, and keep MRI lesion activity low. That’s according to up to 3.5 years of data from a Phase 2 trial (NCT02975349) and its open-label…

Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…

Ocrevus (ocrelizumab), an anti-CD20 therapy developed by Genentech, seems to be superior to rituximab at lowering relapse rates among patients with relapsing-remitting multiple sclerosis (RRMS), according to data from two large MS registries. Overall, the findings suggest that rituximab cannot be considered just as good as —…

Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and reducing disability in people with highly active relapsing-remitting multiple sclerosis (RRMS). In turn, aHSCT appears to be as effective as Ocrevus (ocrelizumab) in RRMS patients and also was…